Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 22.89 yuan on November 4, 2025, down 2.35% from the previous day [1] Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, an increase of 3.28% year-on-year [3] - The net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% year-on-year [3] - The third quarter of 2025 saw a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, up 5.89% year-on-year [3] Market Activity - On November 4, 2025, the net outflow of main funds was 3.6489 million yuan, accounting for 4.48% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuating fund flows, with significant net outflows from main funds on several days [2] Industry Comparison - Meihao Medical's total market value is 13.021 billion yuan, which is higher than the industry average of 11.456 billion yuan [3] - The company's price-to-earnings ratio (P/E) is 46.91, which is lower than the industry average of 60.95, indicating a relatively favorable valuation [3] - The gross profit margin of Meihao Medical is 39.34%, significantly lower than the industry average of 51.22% [3] Analyst Ratings - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings [4] - The average target price set by institutions over the past 90 days is 25.2 yuan [4]
股票行情快报：美好医疗（301363）11月4日主力资金净卖出364.89万元